1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860–921
2. FDA. Innovation or stagnation. Challenge and opportunity on the Critical Path to new medical products. 2004. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
3. Charles River Associates. Innovation in the pharmaceutical sector. A study undertaken for the European Commission. 2004. http://europa.eu.int/comm/enterprise/pharmaceuticals/pharmacos/docs/doc2004/nov/eu_pharma_innovation_25-11-04.pdf
4. Henderson JA, Smith JJ. Realizing the potential for biomarkers in imaging: background and legal basis. Food Drug Law J 2005;60:511–524
5. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151–185